Moxifloxacin for bronchiectasis: long-term safety study
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether a 12-week course of the antibiotic moxifloxacin can safely reduce flare-ups in people with bronchiectasis. It looks at long-term safety and how well the drug works to prevent exacerbations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have bronchiectasis that is not caused by cystic fibrosis, confirmed by a CT scan.
- You have had at least 2 flare-ups (worsening of symptoms) in the past year.
- You are not allergic to moxifloxacin or similar antibiotics (fluoroquinolones).
- You do not have severe liver or kidney disease, and you are not pregnant or breastfeeding.
- You do not have a history of heart rhythm problems and are not taking certain heart rhythm medications.
- You have not been on daily antibiotics to prevent flare-ups in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a common antibiotic called azithromycin can help prevent flare-ups (sudden worsening) of bronchiectasis—a lung condition where airways become permanently enlarged and damaged. Patients will take azithromycin or a placebo for 12 months to see if it reduces how often they get sick.
This study helps doctors understand how severe your bronchiectasis is and predict when you might have flare-ups. You'll have routine tests over 12 months to help researchers learn more about this condition and improve future care.
This study tests if giving antibiotics (levofloxacin or gentamicin) directly into the lungs during a bronchoscopy can help patients with bronchiectasis who are in the hospital with a sudden worsening of symptoms or are on a breathing machine.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study looks at what factors are linked to flare-ups and serious outcomes in people with non–cystic fibrosis bronchiectasis. You may be followed because your lung scans and recent stability help researchers understand what predicts worsening.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
Hear when a new Bronchiectasis, Non-Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.